Effect of olmesartan on oxidative stress in hemodialysis patients

Hypertension Research

Volumn 30, Issue 5, 2007, Pages 395-402

  Kadowaki, Daisuke ^a   Anraku, Makoto ^a   Tasaki, Yuka ^a   Kitamura, Kenichiro ^b   Wakamatsu, Shiho ^b   Tomita, Kimio ^b   Gebicki, Janusz M ^c   Maruyama, Toru ^a   Otagiri, Masaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

Albumin; Blood pressure; Hemodialysis; Olmesartan; Oxidative stress

Indexed keywords

ALBUMIN; HYDROPEROXIDE; OLMESARTAN; PLACEBO;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; OXIDATIVE STRESS; PROTEIN DETERMINATION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIOXIDANTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION, RENAL; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDES; PLACEBOS; RENAL DIALYSIS; SERUM ALBUMIN; TETRAZOLES; UREMIA;

EID: 34250731872     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.395     Document Type: Article

References (40)

1. Suzuki H: Treatment of hypertension in chronic renal insufficiency. Intern Med 2000; 39: 773-777.
2. Suzuki H: Angiotensin type 1 receptor blockers in chronic kidney disease. Contrib Nephrol 2004; 143: 159-166.
3. Okada K, Hirano T, Ran J, Adachi M: Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 2004; 27: 293-299.
4. Mizuno M, Sada T, Kato M, Koike H: Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002; 25: 271-278.
5. Martina B, Dieterle T, Sigle JP, Surber C, Battegay E: Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial. Cardiology 2003; 99: 169-170.
6. Koh KK, Alin JY, Han SH, et al: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-910.
7. Chiendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
8. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J: Angiotensin II activates nuclear transcription factor κB through AT1 and AT2 in vascular smooth muscle cells: Molecular mechanisms. Circ Res 2000; 86: 1266-1272.
9. Tschudi MR, Mesaros S, Luscher TF, Malinski T: Direct in situ measurement of nitric oxide in mesenteric resistance arteries: Increased decomposition by superoxide in hypertension. Hypertension 1996; 27: 32-35.
10. Weiss D, Kools JJ, Taylor WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in ApoE-deficient mice. Circulation 2001; 103: 448-454.
11. Haller H, Viberti GC, Mimran A, et al: Preventing microalbuminuria in patients with diabetes: Rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24: 403-408.
12. Yamaguchi K, Ura N, Murakami H, et al: Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle. Hypertens Res 2005; 28: 773-778;
13. Izuhara Y, Nangaku M, Inagi R, et al: Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16: 3631-3641.
14. Yuan Z, Nimata M, Okabe TA, et al: Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol 2005; 289: H1147-H1152,
15. Miyata T, van Ypersele de Strihou C, Ueda Y, et al: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487.
16. Anraku M, Kitamura K, Shinohara A, et al: Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2004; 66: 841-848.
17. Shimada H, Kitamura K, Anraku M, et al: Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients. Hypertens Res 2005; 28: 987-994.
18. Mera K, Anraku M, Kitamura K, et al: Oxidation and carboxy methyl lysine-modification of albumin: Possible involvement in the progression of oxidative stress in hemodialysis patients. Hypertens Res 2005; 28: 973-980.
19. Gay CA, Gebicki JM: Measurement of protein and lipid hydroperoxides in biological systems by the ferric-xylenol orange method. Anal Biochem 2003; 315: 29-35.
20. Shacter E, Williams JA, Lim M, Levine RL: Differential susceptibility of plasma proteins to oxidative modification: Examination by western blot immunoassay. Free Radic Biol Med 1994; 17: 429-437.
21. Descamps-Latscha B, Witko-Sarsat V: Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 2001; 59 (Suppl 78): S108-S113.
22. Daschner M, Lenhartz H, Botticher D, et al: Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 1996; 50: 1268-1272.
23. Witko-Sarsat V, Gausson V, Nguyen AT, et al: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82-91.
24. Witko-Sarsat V, Gausson V, Descamps-Latscha B: Are advanced oxidation protein products potential uremic toxins? Kidney Int 2003; 63 (Suppl 84): S11-S14.
25. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
26. Odetti P, Garibaldi S, Gurreri G, Aragno I, Dapino D: Protein oxidation in hemodialysis and kidney transplantation. Metabolism 1996; 45 1319-1322.
27. Himmelfarb J, McMonagle E: Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358-363.
28. Bourdon E, Loreau N, Blache D: Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J 1999; 13: 233-244.
29. Gebicki JM: Protein hydroperoxides as new reactive oxygen species. Redox Rep 1997; 3: 99-110.
30. Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M: The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005; 334: 1322-1338.
31. Sogami M, Nagaoka S, Era S, Honda M, Noguchi K: Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int J Pept Protein Res 1984; 24: 96-103.
32. Hayakawa A, Kuwata K, Era S, et al: Alteration of redox state of human serum albumin in patients under anesthesia and invasive surgery. J Chromatogr B Biomed Sci Appl 1997; 698: 27-33.
33. Sogami M, Era S, Nagaoka S, et al: High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. J Chromatogr 1985; 332: 19-27.
34. Suzuki E, Yasuda K, Takeda N, et al: Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract 1992; 18: 153-158.
35. Soejima A, Kaneda F, Manno S, et al: Useful markers for detecting decreased serum antioxidant activity in hemodialysis patients. Am J Kidney Dis 2002; 39: 1040-1046.
36. Soriani M, Pietraforte D, Minetti M: Antioxidant potential of anaerobic human plasma: Role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys 1994; 312: 180-188.
37. Stamler IS, Simon DI, Osborne JA, et al: S-Nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992; 89 444 448.
38. Unger T, Culman J, Gohlke P: Angiotensin II receptor blockade and end-organ protection: Pharmacological rationale and evidence. J Hypertens Suppl 1998; 16: S3-S9.
39. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-2216.
40. Yao L, Kobori H, Rahman M, et al: Olmesartan improves endothelin-induced hypertension and oxidative stress in rats. Hypertens Res 2004; 27: 493-500.